Skip to main content
. 2020 Jun 25;10(12):2323–2338. doi: 10.1016/j.apsb.2020.06.008

Figure 4.

Figure 4

Baicalein decreased HSV-1-EGFP infection. (A) and (B) HaCat cells were infected with HSV-1-EGFP (MOI = 1) for 2 h, and then treated with various concentrations of baicalein for 24 h. The rate of viral infection and plaque inhibition were quantified by EGFP fluorescence and PFU assay, respectively (n = 3). (C) and (D) HaCat cells were infected with HSV-1-EGFP (MOI = 1) and treated with baicalein (100 μmol/L) for 24 or 48 h post-infection. The infected cells were analyzed by fluorescence microscopy and flow cytometry (n = 3). Scale bars = 100 μm. (E) Murine epidermal sheets were challenged with HSV-1-EGFP (MOI = 10) for 2 h, and then cultured in the presence of baicalein (100 μmol/L) or acyclovir (50 μmol/L). At 24 h post-infection, the EGFP signal in epidermal sheets was detected by fluorescence microscopy (n = 3). Scale bars = 50 μm. (F) and (G) Virus titers and GB mRNA expression in epidermal sheets were determined by PFU assay and RT-qPCR, respectively (n = 3). Data are presented as mean ± SD. **P < 0.01, ***P < 0.001 vs. HSV-1 group.